Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

The Future of Pharmacological Treatment in Idiopathic Pulmonary Fibrosis.

Molina-Molina M.

Arch Bronconeumol. 2019 Jun 25. pii: S0300-2896(19)30260-1. doi: 10.1016/j.arbres.2019.05.008. [Epub ahead of print] Review. English, Spanish.

2.

Diagnostic Likelihood Thresholds that Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis.

Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, Inoue Y, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU.

Am J Respir Crit Care Med. 2019 Jun 26. doi: 10.1164/rccm.201903-0493OC. [Epub ahead of print]

PMID:
31241357
3.

Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry.

Fernández-Fabrellas E, Molina-Molina M, Soriano JB, Portal JAR, Ancochea J, Valenzuela C, Xaubet A; SEPAR-IPF National Registry.

Respir Res. 2019 Jun 17;20(1):127. doi: 10.1186/s12931-019-1084-0.

4.

Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study.

Suarez-Cuartin G, Molina-Molina M.

Breathe (Sheff). 2019 Jun;15(2):144-146. doi: 10.1183/20734735.0016-2019.

5.

Hypersensitivity Pneumonitis: Current Concepts of Pathogenesis and Potential Targets for Treatment.

Vasakova M, Selman M, Morell F, Sterclova M, Molina-Molina M, Raghu G.

Am J Respir Crit Care Med. 2019 May 31. doi: 10.1164/rccm.201903-0541PP. [Epub ahead of print]

PMID:
31150272
6.

Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis.

Kreuter M, Lederer DJ, Molina-Molina M, Noth I, Valenzuela C, Frankenstein L, Weycker D, Atwood M, Kirchgaessler KU, Cottin V.

Chest. 2019 Apr 29. pii: S0012-3692(19)30882-7. doi: 10.1016/j.chest.2019.04.015. [Epub ahead of print]

7.

Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.

Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Kim DS, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundy JS, O'Riordan T, Strek ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Worboys AM, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):199-208. doi: 10.1164/rccm.201810-1891OC.

8.

Genetic analyses of aplastic anemia and idiopathic pulmonary fibrosis patients with short telomeres, possible implication of DNA-repair genes.

Arias-Salgado EG, Galvez E, Planas-Cerezales L, Pintado-Berninches L, Vallespin E, Martinez P, Carrillo J, Iarriccio L, Ruiz-Llobet A, Catalá A, Badell-Serra I, Gonzalez-Granado LI, Martín-Nalda A, Martínez-Gallo M, Galera-Miñarro A, Rodríguez-Vigil C, Bastos-Oreiro M, Perez de Nanclares G, Leiro-Fernández V, Uria ML, Diaz-Heredia C, Valenzuela C, Martín S, López-Muñiz B, Lapunzina P, Sevilla J, Molina-Molina M, Perona R, Sastre L.

Orphanet J Rare Dis. 2019 Apr 17;14(1):82. doi: 10.1186/s13023-019-1046-0.

9.

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation.

Maher TM, Lancaster LH, Jouneau S, Morrison L, Lederer DJ, Molina-Molina M, Bendstrup E, Kirchgaessler KU, Gilberg F, Axmann J, Petzinger U, Noble PW.

Ann Am Thorac Soc. 2019 Jul;16(7):927-930. doi: 10.1513/AnnalsATS.201810-720RL. No abstract available.

10.

Research highlights from the 2018 ERS International Congress: interstitial lung diseases.

Alfaro TM, Moor CC, Alfieri V, Jeny F, Kreuter M, Wijsenbeek MS, Renzoni EA, Bargagli E, Nunes H, Spagnolo P, Bonella F, Molina-Molina M, Antoniou K, Poletti V.

ERJ Open Res. 2019 Feb 18;5(1). pii: 00215-2018. doi: 10.1183/23120541.00215-2018. eCollection 2019 Feb. Review.

11.

Interstitial Lung Diseases in Developing Countries.

Rivera-Ortega P, Molina-Molina M.

Ann Glob Health. 2019 Jan 22;85(1). pii: 4. doi: 10.5334/aogh.2414. Review.

PMID:
30741505
12.

Telomere Shortening Behind the Harm of Immunosuppressive Therapy In Idiopathic Pulmonary Fibrosis.

Molina-Molina M.

Am J Respir Crit Care Med. 2019 Jan 9. doi: 10.1164/rccm.201812-2330ED. [Epub ahead of print] No abstract available.

PMID:
30624965
13.

Correction: Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness.

Ruiz de Garibay G, Herranz C, Llorente A, Boni J, Serra-Musach J, Mateo F, Aguilar H, Gómez-Baldó L, Petit A, Vidal A, Climent F, Hernández-Losa J, Cordero Á, González-Suárez E, Sánchez-Mut JV, Esteller M, Llatjós R, Varela M, López JI, García N, Extremera AI, Gumà A, Ortega R, Plà MJ, Fernández A, Pernas S, Falo C, Morilla I, Campos M, Gil M, Román A, Molina-Molina M, Ussetti P, Laporta R, Valenzuela C, Ancochea J, Xaubet A, Casanova Á, Pujana MA.

PLoS One. 2018 Nov 12;13(11):e0207586. doi: 10.1371/journal.pone.0207586. eCollection 2018.

14.

Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis.

Machahua C, Montes-Worboys A, Planas-Cerezales L, Buendia-Flores R, Molina-Molina M, Vicens-Zygmunt V.

Respir Res. 2018 Nov 8;19(1):215. doi: 10.1186/s12931-018-0924-7.

15.

Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series.

Narváez J, LLuch J, Alegre Sancho JJ, Molina-Molina M, Nolla JM, Castellví I.

Ann Rheum Dis. 2018 Oct 23. pii: annrheumdis-2018-214449. doi: 10.1136/annrheumdis-2018-214449. [Epub ahead of print] No abstract available.

PMID:
30352892
16.

Predictive factors and prognostic effect of telomere shortening in pulmonary fibrosis.

Planas-Cerezales L, Arias-Salgado EG, Buendia-Roldán I, Montes-Worboys A, López CE, Vicens-Zygmunt V, Hernaiz PL, Sanuy RL, Leiro-Fernandez V, Vilarnau EB, Llinás ES, Sargatal JD, Abellón RP, Selman M, Molina-Molina M.

Respirology. 2019 Feb;24(2):146-153. doi: 10.1111/resp.13423. Epub 2018 Oct 15.

17.

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial.

Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Cottin V.

BMJ Open Respir Res. 2018 Sep 4;5(1):e000289. doi: 10.1136/bmjresp-2018-000289. eCollection 2018.

18.

Identification of MMP28 as a biomarker for the differential diagnosis of idiopathic pulmonary fibrosis.

Maldonado M, Buendía-Roldán I, Vicens-Zygmunt V, Planas L, Molina-Molina M, Selman M, Pardo A.

PLoS One. 2018 Sep 12;13(9):e0203779. doi: 10.1371/journal.pone.0203779. eCollection 2018.

19.

Production via good manufacturing practice of exofucosylated human mesenchymal stromal cells for clinical applications.

López-Lucas MD, Pachón-Peña G, García-Hernández AM, Parrado A, Sánchez-Salinas D, García-Bernal D, Algueró MDC, Martinez FI, Blanquer M, Cabañas-Perianes V, Molina-Molina M, Asín-Aguilar C, Moraleda JM, Sackstein R.

Cytotherapy. 2018 Sep;20(9):1110-1123. doi: 10.1016/j.jcyt.2018.07.001. Epub 2018 Aug 29.

PMID:
30170815
20.

Pleuropulmonary fibroelastosis in a patient with systemic lupus erythematosus.

Morales-Ivorra I, Molina-Molina M, Narváez J.

Med Clin (Barc). 2019 Jun 21;152(12):513-514. doi: 10.1016/j.medcli.2018.06.004. Epub 2018 Aug 20. English, Spanish. No abstract available.

PMID:
30139584
21.

Clinical implications of telomere dysfunction in lung fibrosis.

Molina-Molina M, Borie R.

Curr Opin Pulm Med. 2018 Sep;24(5):440-444. doi: 10.1097/MCP.0000000000000506. Review.

PMID:
30067250
22.

The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target.

Galán-Cobo A, Arellano-Orden E, Sánchez Silva R, López-Campos JL, Gutiérrez Rivera C, Gómez Izquierdo L, Suárez-Luna N, Molina-Molina M, Rodríguez Portal JA, Echevarría M.

Front Mol Biosci. 2018 May 3;5:43. doi: 10.3389/fmolb.2018.00043. eCollection 2018.

23.

Importance of early diagnosis and treatment in idiopathic pulmonary fibrosis.

Molina-Molina M, Aburto M, Acosta O, Ancochea J, Rodríguez-Portal JA, Sauleda J, Lines C, Xaubet A.

Expert Rev Respir Med. 2018 Jul;12(7):537-539. doi: 10.1080/17476348.2018.1472580. Epub 2018 May 7. No abstract available.

PMID:
29718749
24.

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells.

Molina-Molina M, Machahua-Huamani C, Vicens-Zygmunt V, Llatjós R, Escobar I, Sala-Llinas E, Luburich-Hernaiz P, Dorca J, Montes-Worboys A.

BMC Pulm Med. 2018 Apr 27;18(1):63. doi: 10.1186/s12890-018-0626-4.

25.

[Acute renal damage secondary to acute tubulointerstitial nephritis drug use. Case report].

Oikonomopoulou N, Martínez López AB, Urbano Villaescusa J, Molina Molina MDC, Butragueño Laiseca L, Barraca Nuñez D, Álvarez Blanco O.

Rev Chil Pediatr. 2017 Dec;88(6):787-791. doi: 10.4067/S0370-41062017000600787. Spanish.

26.

Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation.

Justet A, Thabut G, Manali E, Molina Molina M, Kannengiesser C, Cadranel J, Cottin V, Gondouin A, Nunes H, Magois E, Tromeur C, Prevot G, Papiris S, Marchand-Adam S, Gamez AS, Reynaud-Gaubert M, Wemeau L, Crestani B, Borie R.

Eur Respir J. 2018 Mar 15;51(3). pii: 1701875. doi: 10.1183/13993003.01875-2017. Print 2018 Mar. No abstract available.

PMID:
29449422
27.

Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?

Wolters PJ, Blackwell TS, Eickelberg O, Loyd JE, Kaminski N, Jenkins G, Maher TM, Molina-Molina M, Noble PW, Raghu G, Richeldi L, Schwarz MI, Selman M, Wuyts WA, Schwartz DA.

Lancet Respir Med. 2018 Feb;6(2):154-160. doi: 10.1016/S2213-2600(18)30007-9. Review.

28.

The JAK2 pathway is activated in idiopathic pulmonary fibrosis.

Milara J, Hernandez G, Ballester B, Morell A, Roger I, Montero P, Escrivá J, Lloris JM, Molina-Molina M, Morcillo E, Cortijo J.

Respir Res. 2018 Feb 6;19(1):24. doi: 10.1186/s12931-018-0728-9.

29.

Characterization of Novel Missense Variants of SERPINA1 Gene Causing Alpha-1 Antitrypsin Deficiency.

Matamala N, Lara B, Gomez-Mariano G, Martínez S, Retana D, Fernandez T, Silvestre RA, Belmonte I, Rodriguez-Frias F, Vilar M, Sáez R, Iturbe I, Castillo S, Molina-Molina M, Texido A, Tirado-Conde G, Lopez-Campos JL, Posada M, Blanco I, Janciauskiene S, Martinez-Delgado B.

Am J Respir Cell Mol Biol. 2018 Jun;58(6):706-716. doi: 10.1165/rcmb.2017-0179OC.

PMID:
29232161
30.

Towards a global initiative for fibrosis treatment (GIFT).

Molina-Molina M, Agusti A, Crestani B, Schwartz DA, Königshoff M, Chambers RC, Maher TM, Faner R, Mora AL, Rojas M, Antoniou KM, Sellares J.

ERJ Open Res. 2017 Dec 1;3(4). pii: 00106-2017. doi: 10.1183/23120541.00106-2017. eCollection 2017 Oct.

31.

Epithelial contribution to the profibrotic stiff microenvironment and myofibroblast population in lung fibrosis.

Gabasa M, Duch P, Jorba I, Giménez A, Lugo R, Pavelescu I, Rodríguez-Pascual F, Molina-Molina M, Xaubet A, Pereda J, Alcaraz J.

Mol Biol Cell. 2017 Dec 15;28(26):3741-3755. doi: 10.1091/mbc.E17-01-0026. Epub 2017 Oct 18.

32.

Erratum to "Guidelines for the medical treatment of idiopathic pulmonary fibrosis" <[Arch Bronconeumol. 53 (2017) 263-9] >.

Xaubet A, Molina-Molina M, Acosta O, Bollo E, Castillo D, Fernández-Fabrellas E, Rodríguez-Portal JA, Valenzuela C, Ancochea J.

Arch Bronconeumol. 2017 Nov;53(11):657-658. doi: 10.1016/j.arbres.2017.06.010. Epub 2017 Sep 18. English, Spanish. No abstract available.

33.

Telomere Shortening in Idiopathic Pulmonary Fibrosis.

Molina-Molina M, Planas-Cerezales L, Perona R.

Arch Bronconeumol. 2018 Jan;54(1):3-4. doi: 10.1016/j.arbres.2017.07.026. Epub 2017 Sep 14. English, Spanish. No abstract available.

34.

Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.

Maher TM, Molina-Molina M, Russell AM, Bonella F, Jouneau S, Ripamonti E, Axmann J, Vancheri C.

BMC Pulm Med. 2017 Sep 15;17(1):124. doi: 10.1186/s12890-017-0468-5.

35.

Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.

Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium.

Eur Respir J. 2017 Aug 31;50(2). pii: 1700936. doi: 10.1183/13993003.00936-2017. Print 2017 Aug.

36.

Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: Cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain.

Mañá J, Rubio-Rivas M, Villalba N, Marcoval J, Iriarte A, Molina-Molina M, Llatjos R, García O, Martínez-Yélamos S, Vicens-Zygmunt V, Gámez C, Pujol R, Corbella X.

Medicine (Baltimore). 2017 Jul;96(29):e7595. doi: 10.1097/MD.0000000000007595.

37.

Guidelines for the medical treatment of idiopathic pulmonary fibrosis.

Xaubet A, Molina-Molina M, Acosta O, Bollo E, Castillo D, Fernández-Fabrellas E, Rodríguez-Portal JA, Valenzuela C, Ancochea J.

Arch Bronconeumol. 2017 May;53(5):263-269. doi: 10.1016/j.arbres.2016.12.011. Epub 2017 Mar 11. English, Spanish. Erratum in: Arch Bronconeumol. 2017 Nov;53(11):657-658.

38.

Idiopathic pulmonary fibrosis.

Xaubet A, Ancochea J, Molina-Molina M.

Med Clin (Barc). 2017 Feb 23;148(4):170-175. doi: 10.1016/j.medcli.2016.11.004. Epub 2016 Dec 18. Review. English, Spanish.

PMID:
27998476
39.

Increased AGE-RAGE ratio in idiopathic pulmonary fibrosis.

Machahua C, Montes-Worboys A, Llatjos R, Escobar I, Dorca J, Molina-Molina M, Vicens-Zygmunt V.

Respir Res. 2016 Nov 5;17(1):144.

40.

Shrinking lung syndrome in systemic lupus erythematosus: A case series and review of the literature.

Borrell H, Narváez J, Alegre JJ, Castellví I, Mitjavila F, Aparicio M, Armengol E, Molina-Molina M, Nolla JM.

Medicine (Baltimore). 2016 Aug;95(33):e4626. doi: 10.1097/MD.0000000000004626. Review.

41.

Dendriform Pulmonary Ossification in a Subclinical Case of Familial Pulmonary Fibrosis.

Diez-Ferrer M, Luburich P, Llatjós R, Xaubet A, Dorca J, Molina-Molina M.

Arch Bronconeumol. 2016 Dec;52(12):e9-e10. doi: 10.1016/j.arbres.2016.05.009. Epub 2016 Jul 5. English, Spanish. No abstract available.

42.

European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity.

Bonella F, Wijsenbeek M, Molina-Molina M, Duck A, Mele R, Geissler K, Wuyts W.

Eur Respir J. 2016 Jul;48(1):283-4. doi: 10.1183/13993003.00604-2016. No abstract available.

43.

[Lymphoproliferative pulmonary infiltration: A diagnosis to keep in mind in pulmonary infiltrates in patient with chronic lymphocytic leukemia].

González-Fernández C, Dorca J, Molina-Molina M.

Med Clin (Barc). 2016 Sep 2;147(5):224-225. doi: 10.1016/j.medcli.2016.03.024. Epub 2016 May 12. Spanish. No abstract available.

PMID:
27181216
44.

Systemic and Pulmonary Vascular Remodelling in Chronic Obstructive Pulmonary Disease.

Muñoz-Esquerre M, López-Sánchez M, Escobar I, Huertas D, Penín R, Molina-Molina M, Manresa F, Dorca J, Santos S.

PLoS One. 2016 Apr 5;11(4):e0152987. doi: 10.1371/journal.pone.0152987. eCollection 2016.

45.

Study of breast cancer incidence in patients of lymphangioleiomyomatosis.

Nuñez O, Román A, Johnson SR, Inoue Y, Hirose M, Casanova Á, de Garibay GR, Herranz C, Bueno-Moreno G, Boni J, Mateo F, Petit A, Climent F, Soler T, Vidal A, Sánchez-Mut JV, Esteller M, López JI, García N, Gumà A, Ortega R, Plà MJ, Campos M, Ansótegui E, Molina-Molina M, Valenzuela C, Ussetti P, Laporta R, Ancochea J, Xaubet A, Pollán M, Pujana MA.

Breast Cancer Res Treat. 2016 Feb;156(1):195-201. doi: 10.1007/s10549-016-3737-8. Epub 2016 Mar 7.

46.

Preclinical lung disease in early rheumatoid arthritis.

Robles-Perez A, Luburich P, Rodriguez-Sanchon B, Dorca J, Nolla JM, Molina-Molina M, Narvaez-Garcia J.

Chron Respir Dis. 2016 Feb;13(1):75-81. doi: 10.1177/1479972315620746.

47.

[Alopecia areata secondary to the use of leflunomide in patients with rheumatoid arthritis: a case report and literature review].

Molina Molina MI, Pinochet Paiva CM, Quezada Morales JI.

Medwave. 2015 Dec 30;15(11):e6350. doi: 10.5867/medwave.2015.11.6350. Review. Spanish.

PMID:
26819061
48.

Inflammatory markers and circulating extracellular matrix proteins in patients with chronic obstructive pulmonary disease and left ventricular diastolic dysfunction.

López-Sánchez M, Muñoz-Esquerre M, Huertas D, Montes A, Molina-Molina M, Manresa F, Dorca J, Santos S.

Clin Respir J. 2017 Nov;11(6):859-866. doi: 10.1111/crj.12428. Epub 2016 Jan 6.

PMID:
26663885
49.

European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers.

Bonella F, Wijsenbeek M, Molina-Molina M, Duck A, Mele R, Geissler K, Wuyts W.

Eur Respir J. 2016 Feb;47(2):597-606. doi: 10.1183/13993003.01204-2015. Epub 2015 Nov 19.

50.

Erratum to: Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices.

Vicens-Zygmunt V, Estany S, Colom A, Montes-Worboys A, Machahua C, Sanabria AJ, Llatjos R, Escobar I, Manresa F, Dorca J, Navajas D, Alcaraz J, Molina-Molina M.

Respir Res. 2015 Nov 2;16:136. doi: 10.1186/s12931-015-0277-4. No abstract available.

Supplemental Content

Loading ...
Support Center